Longeveron (LGVN) Profit After Tax (2020 - 2026)
Longeveron (LGVN) recorded quarterly Profit After Tax of -$4.7 million in Q1 2026, up 12.36% quarter-over-quarter from -$5.4 million in Q4 2025, and up 5.28% on a YoY basis from -$4.5 million in Q1 2025.
Longeveron (LGVN) Profit After Tax (2020 - 2026) Analysis & Trends
Longeveron's Profit After Tax history runs 7 years deep, the most recent figure standing at -$4.7 million for Q1 2026.
- In Q1 2026, Profit After Tax rose 5.28% year-over-year to -$4.7 million; the TTM figure through Mar 2026 stood at -$22.4 million (down 32.23% YoY), while the FY2025 annual figure was -$22.7 million, down 41.9% from the prior year.
- Profit After Tax was -$4.7 million for Q1 2026 at Longeveron, up from -$5.4 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$3.4 million in Q2 2024 to a low of -$7.2 million in Q3 2025.
- Historically, Profit After Tax has averaged -$4.9 million across 5 years, with a median of -$5.0 million in 2025.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax soared 39.4% in 2024, then tumbled 63.41% in 2025.
- A 5-year view of Profit After Tax shows it stood at -$4.5 million in 2022, then sank by 34.62% to -$6.0 million in 2023, then jumped by 31.67% to -$4.1 million in 2024, then slumped by 31.8% to -$5.4 million in 2025, then increased by 12.36% to -$4.7 million in 2026.
- The last three Profit After Tax figures came in at -$4.7 million (Q1 2026), -$5.4 million (Q4 2025), and -$7.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | -4.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.74 Mn |
| Dec 31, 2025 | -5.40 Mn |
| Sep 30, 2025 | -7.22 Mn |
| Jun 30, 2025 | -5.03 Mn |
| Mar 31, 2025 | -5.00 Mn |
| Dec 31, 2024 | -4.10 Mn |
| Sep 30, 2024 | -4.42 Mn |
| Jun 30, 2024 | -3.41 Mn |
| Mar 31, 2024 | -4.10 Mn |
| Dec 31, 2023 | -6.00 Mn |
| Sep 30, 2023 | -5.11 Mn |
| Jun 30, 2023 | -5.63 Mn |
| Mar 31, 2023 | -4.60 Mn |
| Dec 31, 2022 | -4.46 Mn |
| Sep 30, 2022 | -5.24 Mn |
| Jun 30, 2022 | -5.62 Mn |
| Mar 31, 2022 | -3.51 Mn |
| Dec 31, 2021 | -4.07 Mn |
| Sep 30, 2021 | -4.86 Mn |
| Jun 30, 2021 | -5.01 Mn |